Reading ELTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ELTX free→Reading ELTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ELTX free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been steady, but risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, ELTX is typical. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $14.85. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $15 ELTX trades at 16× p/s — 1.7× the 9× p/s peer median. The market is re-rating it beyond its own range; our $10 fair value is medium-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 43% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.96x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
5 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.40 → $-0.53 (-33.3% / 30d). 0 raised, 1 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$351.
How much price usually moves either way.
On a bad day, this stock has moved -$646.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,610.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'None' to 'expensive'.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If healthcare sector growth speeds up, it may benefit Elicio. This could improve investor sentiment.
Confirms:Healthcare sector revenue growth is speeding up again. It is now above 10%.
Disproves:Healthcare sector revenue growth is slowing down. It is now below 10%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ELTX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 11, 2026 , Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securiti…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ELTX Elicio Therapeutics Inc | Typical Show detailsSector percentile: 30 of 100 | expensive | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to extend the cash runway into the fourth quarter of 2026, beyond the anticipated DFS readout.
Stated in 3 of last 3 quarters. Management has consistently aimed to extend the cash runway into Q4 2026. However, financials show persistent negative cash from operations, with -$11.65M in 2026-Q1 and -$6.8M in 2025-Q4, indicating limited progress in achieving this goal.
“With our cash runway now expected to extend into Q4 2026, beyond the anticipated DFS readout...”
“The Company expects its current cash and cash equivalents and projected at-the-market program proceeds to support operations into Q3 2026...”
“we are updating our guidance for the timing of the event-driven primary DFS endpoint analysis to the first half of 2026.”
Management plans to conduct the AMPLIFY-7P Phase 2 event-driven DFS analysis in the first half of 2026.
Stated in 3 of last 3 quarters. Management has reiterated the timing for the AMPLIFY-7P Phase 2 DFS analysis to occur in the first half of 2026. However, the financials show ongoing operating losses, with net income at -$11.82M in 2026-Q1, suggesting challenges in funding this initiative.
“With our cash runway now expected to extend into Q4 2026, beyond the anticipated DFS readout...”
Results of Operations and Financial Condition. On March 12, 2026, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securit…
Entry into a Material Definitive Agreement. On March 16, 2026, Elicio Therapeutics, Inc. (the “ Company ”) entered into an At Market Issuance Sales Agreement (the “ Sales Agreement ”) with B. Riley Securities, Inc., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. (the “ Agents ”) with respect to an at-the-market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share…
Termination of a Material Definitive Agreement. As previously disclosed on June 3, 2024, the Company entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (“Jones”) as sales agent (the “Jones Sales Agreement”), pursuant to which the Company was permitted to issue and sell, from time to time through Jones, shares of the Company’s common stock having an aggregate offering price of up to $40.0 million. On March 16, 2026, the Company delivered written noti…
Results of Operations and Financial Condition. On November 13, 2025, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the…
“The Company expects its current cash and cash equivalents and projected at-the-market program proceeds to support operations into Q3 2026...”
“we are updating our guidance for the timing of the event-driven primary DFS endpoint analysis to the first half of 2026.”